Anthem Biosciences reported a 22.6% year-on-year decline in consolidated revenue from operations to ₹4,182 Mn for the quarter ended June 30, 2026, attributing the drop to timing shifts in customer deliveries rather than demand weakness. Despite the top-line contraction, Profit After Tax (PAT) fell by a narrower 11.7% to ₹1,199 Mn, while EBITDA margins expanded by 153 basis points to 39.6%, reflecting disciplined cost management and yield optimization. Management emphasized that the company retains a strong order book with 60% of annual deliveries already secured, positioning it for recovery in subsequent quarters.

Operational Visibility and Order Book

During the earnings conference call held on July 22, 2026, Managing Director Ajay Bhardwaj and CFO Gawir Baig clarified that the soft Q1 performance is characteristic of the CRDMO business cycle, where delivery schedules are dictated by client needs. The company currently holds an order book representing 60% of its expected full-year revenue, providing high visibility for the remainder of FY27. Bhardwaj noted that deferred deliveries are scheduled for Q2, Q3, and Q4, with capacity utilization expected to rise significantly in the coming quarters. The Specialty Ingredients segment, which contributed ₹774 Mn (18.5% of total revenue), faces domestic supply chain pressures but is expected to recover as raw material markets stabilize.

Capacity Utilization and Expansion Plans

Capacity utilization varied across facilities in Q1FY27. Unit 1 operated at approximately 78% utilization on the custom synthesis side, maintaining levels similar to the previous year. Unit 2, which underwent significant expansion adding 130 kiloliters of custom synthesis capacity, saw utilization drop to 50% due to the softer quarter, though fermentation utilization remained steady at 50% across its 140 kiloliters. Unit 3 (Neo Anthem) showed improvement, rising to 30–35% utilization from roughly 15% in FY26, driven primarily by new projects in peptide synthesis and oncology manufacturing rather than mere production shifting.

To address future demand, Anthem is constructing Unit 4 on a 30-acre site, with Phase 1 set to add 365 kiloliters of custom synthesis and 100 kiloliters of fermentation capacity, along with food and nutraceutical plants. The total capex outlay for Unit 4 is approximately ₹1,200 crore, split evenly between FY27 and FY28. Management expects to commission Unit 4 by the end of FY28. For FY27, targeted capex stands at ₹700 crore, remaining elevated to support this expansion.

Financial Metrics and Margins

The company’s net cash position strengthened significantly to ₹17,197 Mn as of June 30, 2026, up from ₹7,848 Mn in the prior year. Standalone revenue declined to ₹3,838 Mn from ₹5,380 Mn in Q1FY26, with standalone net profit dropping to ₹1,020 Mn. However, management highlighted that effective tax rates are expected to normalize to around 25–25.5% for the full year, compared to higher rates in FY26 driven by losses in the Neo Anthem subsidiary. ESOP expenses for FY27 are estimated at ₹9 crore, down from ₹16 crore in FY26, further supporting margin stability.

What the Numbers Show

The divergence between revenue decline (-22.6%) and PAT decline (-11.7%) underscores Anthem’s operational leverage and pricing power. While top-line growth was muted by logistical deferments, the expansion in EBITDA margins to nearly 40% indicates that cost controls and yield improvements are effectively offsetting volume shortfalls. The robust cash position of ₹17,197 Mn provides ample runway for the ₹700 crore FY27 capex program without diluting equity or increasing debt. With 60% of the annual order book already secured, the risk of further significant downside appears limited, suggesting that the Q1 results represent a temporary trough in a cyclical delivery pattern rather than a structural demand issue.

Anthem Biosciences shareholders approved all eight resolutions at its 20th Annual General Meeting held on July 22, 2026, including the adoption of audited financial statements for FY26 and the declaration of a dividend. The meeting, conducted via video conferencing, saw a robust participation rate of 95.59% of outstanding shares polled across key ordinary resolutions, reflecting strong engagement from both promoter and public stakeholders. While promoter support was unanimous across all agenda items, certain public institutional investors registered dissent on specific governance and related-party matters.

The scrutinizer report, submitted by BMP & Co. LLP under Section 108 of the Companies Act, 2013 and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, confirmed that all resolutions were passed with the requisite majority. The record date for voting was July 17, 2026, with 173,991 shareholders eligible to vote. Remote e-voting commenced on July 19, 2026, and concluded on July 21, 2026, followed by instant polling during the virtual meeting. Ms. Lakshmi M and Ms. Jayashree Sharma acted as independent witnesses for the unblocking of votes on July 22, 2026.

Voting Outcomes by Resolution

Shareholders overwhelmingly supported the adoption of the audited financial statements for the year ended March 31, 2026, and the reports of the Board of Directors and statutory auditors. This ordinary resolution received 100% support from promoters and nearly 100% from public non-institutional investors. The dividend declaration also secured near-unanimous approval, with only 74 votes cast against it out of over 538 million votes polled.

The re-appointment of Mr. K Ravindra Chandrappa (DIN: 01580534), who retires by rotation, was approved with 99.95% support. However, public institutional investors voted against this resolution at a rate of 0.26%, while promoter group support remained at 100%. Similarly, the appointment of M/S. S.R. Batliboi & Associates LLP as statutory auditors saw 99.99% overall support, with minimal dissent from public institutions.

Governance and Related-Party Approvals

A special resolution to approve the continuation of Mr. Ravikant Uppal (DIN: 00025970) as a non-executive independent director upon attaining the age of 75 years was passed with 98.99% support. Notably, public institutional investors voted against this resolution at a rate of 5.87%, indicating some scrutiny regarding tenure limits for independent directors.

The approval of commission payable to independent directors faced the highest level of dissent among all resolutions. While promoters voted unanimously in favor, public institutional investors opposed the resolution by 28.16%, resulting in an overall support rate of 95.19%. This suggests significant debate among large investors regarding director remuneration structures.

The increase in payment of remuneration to related parties holding an office or place of profit was approved with 99.05% support. Promoters abstained from voting on this resolution, leaving the decision entirely to public shareholders. Public institutions showed minor dissent at 1.40%, while non-institutional public shareholders supported the measure almost unanimously.

Strategic Partnership Approval

The final resolution concerned the Upside Sharing Arrangement with Viridity Tone LLP. This ordinary resolution received 85.27% overall support but faced substantial opposition from public institutional investors, who voted against it at a rate of 21.67%. Promoters again abstained from voting on this matter. The arrangement likely involves performance-linked incentives or equity-based rewards, which may have raised concerns among some institutional holders regarding dilution or payout structures.

Mr. Ajay Bhardwaj, Chairperson, Managing Director, and Chief Executive Officer, chaired the meeting. Ms. Divya Prasad, Company Secretary and Compliance Officer, oversaw the proceedings, while Mr. Pramod S M of BMP & Co. LLP served as the scrutinizer. The complete voting results and scrutinizer report are available on the company’s website at https://anthembio.com/ .